Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Maria Isabel Lopes, Leticia P Bonjorno, Marcela C Giannini, Natalia B Amaral, Pamella Indira Menezes, Saulo Musse Dib, Samara Libich Gigante, Maira N Benatti, Uebe C Rezek, Laerte L Emrich-Filho, Betania A A Sousa, Sergio C L Almeida, Rodrigo Luppino Assad, Flavio P Veras, Ayda Schneider, Tamara S Rodrigues, Luiz O S Leiria, Larissa D Cunha, Jose C Alves-Filho, Thiago M Cunha, Eurico Arruda, Carlos H Miranda, Antonio Pazin-Filho, Maria Auxiliadora-Martins, Marcos C Borges, Benedito A L Fonseca, Valdes R Bollela, Cristina M Del-Ben, Fernando Q Cunha, Dario S Zamboni, Rodrigo C Santana, Fernando C Vilar, Paulo Louzada-Junior, Dr Rene D R Oliveira
RMD Open, doi:10.1136/rmdopen-2020-001455
Objective To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes. Design We present the results of a randomised, doubleblinded, placebo-controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 75 patients allocated 1:1 from 11 April to 30 August 2020. Colchicine regimen was 0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days. The primary endpoints were the need for supplemental oxygen, time of hospitalisation, need for admission and length of stay in intensive care unit and death rate. Results Seventy-two patients (36 for placebo and 36 for colchicine) completed the study. Median (and IQR) time of need for supplemental oxygen was 4.0 (2.0-6.0) days for the colchicine group and 6.5 (4.0-9.0) days for the placebo group (p<0.001). Median (IQR) time of hospitalisation was 7.0 (5.0-9.0) days for the colchicine group and 9.0 (7.0-12.0) days for the placebo group (p=0.003). At day 2, 67% versus 86% of patients maintained the need for supplemental oxygen, while at day 7, the values were 9% versus 42%, in the colchicine and the placebo groups, respectively (log rank; p=0.001). Two patients died, both in placebo group. Diarrhoea was more frequent in the colchicine group (p=0.26). Conclusion Colchicine reduced the length of both, supplemental oxygen therapy and hospitalisation. The drug was safe and well tolerated. Once death was an uncommon event, it is not possible to ensure that colchicine reduced mortality of COVID-19. Trial registration number RBR-8jyhxh.
How might this impact on clinical practice?? ► This is the first RCT on colchicine for COVID-19. Colchicine may be considered as an adjunctive therapy for hospitalised patients with moderate to severe COVID-19.
Competing interests None declared. Patient consent for publication Not required. Ethics approval This study was approved by National Ethics Committee (CONEP; CAAE: 30248420.9.3001.5403). Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available on reasonable request. Data types: deidentified participant data. How to access data: renedroliveira@ gmail. com. When available: With publication. Additional information who can access the data: researchers whose proposed use of the data has been approved. Types of analyses: any purpose. Mechanisms of data availability: with investigator support, after approval of a proposal with a signed data access agreement.
Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https:// creativecommons. org/ licenses/ by/ 4. 0/.
References
Broz, Dixit, Inflammasomes: mechanism of assembly, regulation and signalling, Nat Rev Immunol,
doi:10.1038/nri.2016.58Chawla, Nguyen, Goh, Macrophage-Mediated inflammation in metabolic disease, Nat Rev Immunol,
doi:10.1038/nri3071Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.13136Esser, Legrand-Poels, Piette, Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes, Diabetes Res Clin Pract,
doi:10.1016/j.diabres.2014.04.006Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N Engl J Med,
doi:10.1056/NEJMoa2021436Iwasaki, Medzhitov, Control of adaptive immunity by the innate immune system, Nat Immunol,
doi:10.1038/ni.3123Jin, Cai, Cheng, A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version), Mil Med Res,
doi:10.1186/s40779-020-0233-6Kajikawa, Higashi, Tomiyama, Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease, Int J Cardiol,
doi:10.1016/j.ijcard.2019.01.054Mi, Zhong, Huang, Gender, age and comorbidities as the main prognostic factors in patients with COVID-19 pneumonia, Am J Transl Res
Piantoni, Colombo, Airò, The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al, Clin Rheumatol,
doi:10.1007/s10067-020-05232-yRodrigues, De Sá, Ishimoto, Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients, J Exp Med,
doi:10.1084/jem.20201707Rodriguez-Morales, Cardona, Ocampo, Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis, Travel Med Infect Dis
Ruan, Yang, Wang, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med,
doi:10.1007/s00134-020-05991-xSafi, Kallas, Bardawil, Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet's disease, J Dermatol Sci,
doi:10.1016/j.jdermsci.2018.08.010Scarsi, Piantoni, Colombo, Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-217712Tardif, Kouz, Waters, Efficacy and safety of low-dose colchicine after myocardial infarction, N Engl J Med,
doi:10.1056/NEJMoa1912388Veras, Pontelli, Silva, SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology, J Exp Med,
doi:10.1084/jem.20201129Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA,
doi:10.1001/jama.2020.2648Yang, Hu, Zhu, Obesity aggravates COVID-19: a systematic review and meta-analysis, J Med Virol
DOI record:
{
"DOI": "10.1136/rmdopen-2020-001455",
"ISSN": [
"2056-5933"
],
"URL": "http://dx.doi.org/10.1136/rmdopen-2020-001455",
"abstract": "<jats:sec><jats:title>Objective</jats:title><jats:p>To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>We present the results of a randomised, double-blinded, placebo-controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 75 patients allocated 1:1 from 11 April to 30 August 2020. Colchicine regimen was 0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days. The primary endpoints were the need for supplemental oxygen, time of hospitalisation, need for admission and length of stay in intensive care unit and death rate.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Seventy-two patients (36 for placebo and 36 for colchicine) completed the study. Median (and IQR) time of need for supplemental oxygen was 4.0 (2.0–6.0) days for the colchicine group and 6.5 (4.0–9.0) days for the placebo group (p<0.001). Median (IQR) time of hospitalisation was 7.0 (5.0–9.0) days for the colchicine group and 9.0 (7.0–12.0) days for the placebo group (p=0.003). At day 2, 67% versus 86% of patients maintained the need for supplemental oxygen, while at day 7, the values were 9% versus 42%, in the colchicine and the placebo groups, respectively (log rank; p=0.001). Two patients died, both in placebo group. Diarrhoea was more frequent in the colchicine group (p=0.26).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Colchicine reduced the length of both, supplemental oxygen therapy and hospitalisation. The drug was safe and well tolerated. Once death was an uncommon event, it is not possible to ensure that colchicine reduced mortality of COVID-19.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p>RBR-8jyhxh.</jats:p></jats:sec>",
"alternative-id": [
"10.1136/rmdopen-2020-001455"
],
"author": [
{
"ORCID": "http://orcid.org/0000-0002-5060-4289",
"affiliation": [],
"authenticated-orcid": false,
"family": "Lopes",
"given": "Maria Isabel",
"sequence": "first"
},
{
"affiliation": [],
"family": "Bonjorno",
"given": "Leticia P",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Giannini",
"given": "Marcela C",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Amaral",
"given": "Natalia B",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Menezes",
"given": "Pamella Indira",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Dib",
"given": "Saulo Musse",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Gigante",
"given": "Samara Libich",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Benatti",
"given": "Maira N",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Rezek",
"given": "Uebe C",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Emrich-Filho",
"given": "Laerte L",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Sousa",
"given": "Betania A A",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Almeida",
"given": "Sergio C L",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-8430-8357",
"affiliation": [],
"authenticated-orcid": false,
"family": "Luppino Assad",
"given": "Rodrigo",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Veras",
"given": "Flavio P",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Schneider",
"given": "Ayda",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Rodrigues",
"given": "Tamara S",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Leiria",
"given": "Luiz O S",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Cunha",
"given": "Larissa D",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Alves-Filho",
"given": "Jose C",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Cunha",
"given": "Thiago M",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Arruda",
"given": "Eurico",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Miranda",
"given": "Carlos H",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Pazin-Filho",
"given": "Antonio",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Auxiliadora-Martins",
"given": "Maria",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Borges",
"given": "Marcos C",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Fonseca",
"given": "Benedito A L",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Bollela",
"given": "Valdes R",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Del-Ben",
"given": "Cristina M",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Cunha",
"given": "Fernando Q",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zamboni",
"given": "Dario S",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Santana",
"given": "Rodrigo C",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Vilar",
"given": "Fernando C",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Louzada-Junior",
"given": "Paulo",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0003-0229-6864",
"affiliation": [],
"authenticated-orcid": false,
"family": "Oliveira",
"given": "Rene D R",
"sequence": "additional"
}
],
"container-title": "RMD Open",
"container-title-short": "RMD Open",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"bmj.com"
]
},
"created": {
"date-parts": [
[
2021,
2,
6
]
],
"date-time": "2021-02-06T18:54:11Z",
"timestamp": 1612637651000
},
"deposited": {
"date-parts": [
[
2021,
4,
20
]
],
"date-time": "2021-04-20T19:07:42Z",
"timestamp": 1618945662000
},
"funder": [
{
"DOI": "10.13039/501100003593",
"award": [
"425075/2016-8"
],
"doi-asserted-by": "publisher",
"name": "Conselho Nacional de Desenvolvimento Científico e Tecnológico"
},
{
"DOI": "10.13039/501100001807",
"award": [
"2013/08216-2",
"2020/04964-8",
"2020/05288-6",
"2020/05601-6"
],
"doi-asserted-by": "publisher",
"name": "Fundação de Amparo à Pesquisa do Estado de São Paulo"
},
{
"DOI": "10.13039/501100002322",
"doi-asserted-by": "publisher",
"name": "Coordenação de Aperfeiçoamento de Pessoal de Nível Superior"
}
],
"indexed": {
"date-parts": [
[
2024,
4,
9
]
],
"date-time": "2024-04-09T18:26:54Z",
"timestamp": 1712687214314
},
"is-referenced-by-count": 162,
"issue": "1",
"issued": {
"date-parts": [
[
2021,
2
]
]
},
"journal-issue": {
"issue": "1",
"published-online": {
"date-parts": [
[
2021,
2,
4
]
]
},
"published-print": {
"date-parts": [
[
2021,
2
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "unspecified",
"delay-in-days": 2,
"start": {
"date-parts": [
[
2021,
2,
3
]
],
"date-time": "2021-02-03T00:00:00Z",
"timestamp": 1612310400000
}
}
],
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1136/rmdopen-2020-001455",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "239",
"original-title": [],
"page": "e001455",
"prefix": "10.1136",
"published": {
"date-parts": [
[
2021,
2
]
]
},
"published-online": {
"date-parts": [
[
2021,
2,
4
]
]
},
"published-print": {
"date-parts": [
[
2021,
2
]
]
},
"publisher": "BMJ",
"reference": [
{
"DOI": "10.1007/s00134-020-05991-x",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.1"
},
{
"DOI": "10.1056/NEJMoa2002032",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.2"
},
{
"DOI": "10.1016/j.cyto.2020.155190",
"article-title": "Cytokine prediction of mortality in COVID19 patients",
"author": "Mandel",
"doi-asserted-by": "crossref",
"journal-title": "Cytokine",
"key": "2021042008451130000_7.1.e001455.3",
"volume": "134",
"year": "2020"
},
{
"DOI": "10.1128/mSphere.00362-20",
"article-title": "Clinical characteristics and immune injury mechanisms in 71 patients with COVID-19",
"author": "Wu",
"doi-asserted-by": "crossref",
"first-page": "e00362",
"journal-title": "mSphere",
"key": "2021042008451130000_7.1.e001455.4",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1016/j.tmaid.2020.101623",
"doi-asserted-by": "crossref",
"key": "2021042008451130000_7.1.e001455.5",
"unstructured": "Rodriguez-Morales J , Cardona-Ospina A , Gutiérrez-Ocampo E . Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020."
},
{
"DOI": "10.1084/jem.20201129",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.6"
},
{
"DOI": "10.3389/fimmu.2020.00211",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.7"
},
{
"DOI": "10.1038/nri.2016.58",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.8"
},
{
"DOI": "10.1038/ni.3123",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.9"
},
{
"DOI": "10.2174/1381612824666180116095658",
"article-title": "The role of colchicine in the treatment of autoinflammatory diseases",
"author": "Liantinioti",
"doi-asserted-by": "crossref",
"first-page": "690",
"journal-title": "Curr Pharm Des",
"key": "2021042008451130000_7.1.e001455.10",
"volume": "24",
"year": "2018"
},
{
"DOI": "10.1007/s11926-008-0036-3",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.11"
},
{
"DOI": "10.1016/j.jdermsci.2018.08.010",
"article-title": "Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet's disease",
"author": "Safi",
"doi-asserted-by": "crossref",
"first-page": "143",
"journal-title": "J Dermatol Sci",
"key": "2021042008451130000_7.1.e001455.12",
"volume": "92",
"year": "2018"
},
{
"DOI": "10.1007/s10067-020-05232-y",
"article-title": "The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al",
"author": "Piantoni",
"doi-asserted-by": "crossref",
"first-page": "2489",
"journal-title": "Clin Rheumatol",
"key": "2021042008451130000_7.1.e001455.13",
"volume": "39",
"year": "2020"
},
{
"DOI": "10.1136/annrheumdis-2020-217712",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.14"
},
{
"DOI": "10.1001/jamanetworkopen.2020.13136",
"article-title": "Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial",
"author": "Deftereos",
"doi-asserted-by": "crossref",
"journal-title": "JAMA Netw Open",
"key": "2021042008451130000_7.1.e001455.15",
"volume": "3",
"year": "2020"
},
{
"article-title": "Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report",
"author": "Horby",
"journal-title": "N Engl J Med",
"key": "2021042008451130000_7.1.e001455.16",
"year": "2020"
},
{
"DOI": "10.1001/jama.2020.2648",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.17"
},
{
"DOI": "10.1186/s40779-020-0233-6",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.18"
},
{
"article-title": "Gender, age and comorbidities as the main prognostic factors in patients with COVID-19 pneumonia",
"author": "Mi",
"first-page": "6537",
"journal-title": "Am J Transl Res",
"key": "2021042008451130000_7.1.e001455.19",
"volume": "12",
"year": "2020"
},
{
"DOI": "10.1016/j.jbspin.2006.03.006",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.20"
},
{
"DOI": "10.1016/j.diabres.2014.04.006",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.21"
},
{
"DOI": "10.1038/nrcardio.2009.55",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.22"
},
{
"DOI": "10.1038/nri3071",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.23"
},
{
"DOI": "10.1002/jmv.26237",
"doi-asserted-by": "crossref",
"key": "2021042008451130000_7.1.e001455.24",
"unstructured": "Yang J , Hu J , Zhu C . Obesity aggravates COVID-19: a systematic review and meta-analysis. J Med Virol 2020;30."
},
{
"DOI": "10.1056/NEJMoa1912388",
"doi-asserted-by": "publisher",
"key": "2021042008451130000_7.1.e001455.25"
},
{
"DOI": "10.1016/j.ijcard.2019.01.054",
"article-title": "Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease",
"author": "Kajikawa",
"doi-asserted-by": "crossref",
"first-page": "35",
"journal-title": "Int J Cardiol",
"key": "2021042008451130000_7.1.e001455.26",
"volume": "281",
"year": "2019"
},
{
"DOI": "10.1084/jem.20201707",
"article-title": "Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients",
"author": "Rodrigues",
"doi-asserted-by": "crossref",
"journal-title": "J Exp Med",
"key": "2021042008451130000_7.1.e001455.27",
"volume": "218",
"year": "2021"
}
],
"reference-count": 27,
"references-count": 27,
"relation": {},
"resource": {
"primary": {
"URL": "https://rmdopen.bmj.com/lookup/doi/10.1136/rmdopen-2020-001455"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Immunology",
"Immunology and Allergy",
"Rheumatology"
],
"subtitle": [],
"title": "Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1136/crossmarkpolicy",
"volume": "7"
}
